

DATE: April 5, 2022

TO: Health Care Providers

FROM: Ventura County Public Health

SUBJECT: Outpatient Anti-SARS-CoV-2 Therapeutics Update

Ventura County Public Health would like providers to be aware of the recent developments with regard to COVID-19 Therapeutics:

- The California Department of Public Health (CDPH) issued a [CAHAN](#) regarding changes to recommended outpatient therapies.
- At this time, there is no longer a limited supply of COVID-19 therapeutics in most locations. **Effective immediately, all outpatients with [mild to moderate](#) COVID-19 who are at risk for disease progression should be offered treatment**, if eligible and clinically appropriate, based on the product EUA.
- The CDC and Infectious Diseases Society of America (IDSA) are hosting a “**All About Paxlovid**” webinar this **Saturday, April 9<sup>th</sup> from 12:00 pm – 1:00 pm**. Providers are encouraged to attend. Click [here](#) to register.
- A new HHS [Test to Treat Locator](#) went live on 3/30/2022. This locator identifies facilities that can both test for SARS-CoV-2 and dispense COVID-19 oral antiviral medications (Paxlovid [nirmatrelvir/ritonavir] or Molnupiravir [lagevrio]). Currently there are only 2 Test to Treat sites in Ventura County.
- Patients have access to the same oral antiviral medications (Paxlovid, Molnupiravir) if prescribed by their provider:
  - At this time, 35 pharmacies have Paxlovid and 56 pharmacies have Molnupiravir in stock.
  - View the [HHS locator map](#) or [export a listing](#) to discover which pharmacies in Ventura County carry Paxlovid and/or Molnupiravir.
- Sotrovimab is no longer authorized by the [FDA](#) for use in California due to increases of the Omicron sub-variant BA.2. GlaxoSmithKline, who manufactures Sotrovimab, is studying whether treatment with an increased dosage will be active against the BA.2 variant.

## **RESOURCES**

- Liverpool interaction checker: <https://www.covid19-druginteractions.org/checker>
  - What it is: Tool to facilitate prescribing COVID-19 oral antiviral medication by checking potential drug-to-drug interactions between patients' current list of medication and Paxlovid or Molnupiravir.
  - How to utilize: Enter the anti-SARS-CoV-2 drug (e.g., Paxlovid [nirmatrelvir/ritonavir] or Molnupiravir [Iagevrio]) first, then enter patient co-medications. Drug Interactions will display in the far-right column as "Do Not Coadminister" or "No Interaction Expected".
- Important lessons learned:
  - The window of treatment is **narrow and time sensitive**.
  - Providers are strongly encouraged to educate all their patients that can potentially benefit from early anti-SARS-CoV-2 Therapeutics **before** they get infected.
    - As soon as a patient develops S/S associated with SARS-CoV-2, she/he should be educated to test (over the counter highly recommended to ensure fast turnaround) herself/himself. If the test is positive, they should call their primary care provider as soon as possible to obtain the best treatment available for them.
  - Providers may utilize the flyer below to educate patients about the benefit from early COVID-19 treatment:
    - [DON'T DELAY: TEST SOON AND TREAT EARLY](#)
    - [NO SE DEMORE: HAGASE UNA PRUEVA PRONTO PARA COMENZAR EL TRATAMIENTO TEMPRANO](#)